Cynata Therapeutics Limited (CYYNF)
| Market Cap | 26.17M |
| Revenue (ttm) | 1.08M |
| Net Income (ttm) | -5.48M |
| Shares Out | n/a |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 666 |
| Average Volume | 2,308 |
| Open | 0.1500 |
| Previous Close | 0.1500 |
| Day's Range | 0.1500 - 0.1500 |
| 52-Week Range | 0.1370 - 0.1900 |
| Beta | 0.82 |
| RSI | 36.07 |
| Earnings Date | May 28, 2025 |
About Cynata Therapeutics
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; and CYP-006TK,... [Read more]
Financial Performance
In 2024, Cynata Therapeutics's revenue was 2.32 million, an increase of 39.98% compared to the previous year's 1.65 million. Losses were -9.74 million, -31.75% less than in 2023.
Financial numbers in AUD Financial StatementsNews
Cynata Therapeutics Limited (CYYNF) Investor Webinar Transcript
Cynata Therapeutics Limited (OTCPK:CYYNF) Investor Webinar Conference Call February 5, 2025 6:30 PM ET Company Participants Lauren Nowak - Media Relations Kilian Kelly - Chief Executive Officer and Ma...
Mesoblast Needs A Solution To MSC Scalability Issues - Cynata Therapeutics Has An Answer
FDA fails to approve Mesoblast Steroid Refractory Pediatric Graft vs. Host Disease Stem Cell Therapy after FDA advisory board voted 9-1 recommending approval.